• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    99.41 Up 2.96(3.07%) Dec 18, 4:00PM EST
    |After Hours : 99.41 0.00 (0.00%) Dec 18, 6:19PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Alnylam Pharmaceuticals, Inc.
    300 Third Street
    3rd Floor
    Cambridge, MA 02142
    United States - Map
    Phone: 617-551-8200
    Fax: 617-551-8101
    Website: http://www.alnylam.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:165

    Business Summary 

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company’s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver cancers; and ALN-HTT product candidate for the treatment of Huntington’s disease. It has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Monsanto Company; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd./Arrowhead Research Corporation; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; the Massachusetts Institute of Technology; Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc.; The University of British Columbia; Acuitas Therapeutics Inc.; Biogen Idec Inc.; Ascletis BioScience Co., Ltd.; Medtronic, Inc.; and CHDI Foundation, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alnylam Pharmaceuticals, Inc.

    Corporate Governance 
    Alnylam Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John K. Clarke , 60
    Founder, Chairman, Chairman of Nominating & Corp. Governance Committee and Member of Audit Committee
    60.00KN/A
    Dr. John M. Maraganore M.D., Ph.D., 51
    Chief Exec. Officer and Exec. Director
    1.11M8.93M
    Mr. Barry E. Greene , 51
    Pres and Chief Operating Officer
    776.00K2.41M
    Mr. Michael P. Mason , 39
    Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
    339.00K1.50M
    Dr. Akshay K. Vaishnaw M.D., Ph.D., 51
    Chief Medical Officer and Exec. VP
    699.00K2.40M
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders